Irinotecan (CPT-11) is currently approved for the treatment of advanced or metastatic colorectal cancer as a single agent or in combination chemotherapy regimens ([@bib29]; [@bib3]). CPT-11 is a semi-synthetic camptothecin analogue capable of blocking DNA replication and transcription through topoisomerase-I inhibition ([@bib21]). This prodrug has a complex metabolic pathway where the first step is rapid bioactivation to its active metabolite SN-38, by carboxylesterases (CES1 and CES2) expressed in the liver, as well as to a lesser extent in plasma, gastrointestinal (GI) tract, and tumour tissue ([@bib29]). SN-38 is subsequently detoxified by uridine disphosphate glucuronosyltransferases (UGTs), mainly UGT1A1, to form the inactive metabolite SN-38 glucuronide (SN-38G). CPT-11 also undergoes CYP3A4/5-dependent oxidation to form the inactive metabolites M4, APC, and NPC with the latter available for further conversion to SN-38 ([@bib18]). Increased systemic exposure to SN-38 places patients at an elevated risk of developing severe neutropenia as well as diarrhoea, which is thought to involve reconversion of SN-38G to SN-38 via intestinal *β*-glucuronidases ([@bib29]). Currently, although UGT1A1 polymorphisms are considered important, pharmacogenomic variables are not routinely considered when prescribing CPT-11, and dosing tends to be based on body surface area, clinical variables, and history or onset of adverse events ([@bib18]).

The majority of CPT-11 pharmacogenetic studies have focused on the role of *UGT1A1*. Elevation in the level of SN-38, among patients with *UGT1A1\*28* polymorphism, has been linked to severe CPT-11-induced toxicities including neutropenia and diarrhoea ([@bib16]; [@bib31]). Results from a meta-analysis suggest the risk of severe haematological toxicities in homozygous *UGT1A1\*28* patients is dose dependent with those receiving high doses (\>250 mg m^−2^) at the greatest risk. Although variant patients receiving intermediate doses (150--250 mg m^−2^) of CPT-11 are at significantly increased risks compared with patients with at least one wild-type allele, the odds of toxicity may be within an acceptable range if no other risk factors for neutropenia are present ([@bib13]), questioning the usefulness of genotyping patients prescribed low-to-intermediate doses of CPT-11 before administration. Although it appears UGT1A1 has an important role in the development of CPT-11-related adverse events in some patients, there are many lacking known *UGT* polymorphisms who suffer from dose-limiting toxicities during CPT-11 therapy. Indeed, the interplay of numerous genes in the CPT-11 metabolism and disposition pathways is likely the basis for often unpredictably severe toxicity during CPT-11 therapy.

There is an increasing appreciation of the role of drug uptake and efflux transporters, both in organs such as the intestine and liver, as well in tumour, to the disposition and response to drugs in clinic use. We know that uptake transporters, such as OATP1B1 (SLCO1B1) are required for hepatic influx of SN-38, whereas ABC transporters including ABCC1, ABCC2, ABCB1, and ABCG2 regulate the hepatic and biliary efflux of CPT-11 metabolites ([@bib9]). Polymorphisms within *SLCO1B1*, *ABCB1*, and *ABCC2* have recently been associated with modulation of CPT-11 and SN-38 exposure ([@bib16]; [@bib31]). Additional polymorphisms in *ABCG2* and *ABCC5* have recently been correlated with non-haematological toxicities ([@bib7]; [@bib6]). However, pharmacogenetic studies have demonstrated mixed results regarding the role of drug transporters to adverse events and response ([@bib23]; [@bib9]). CPT-11 dose and schedule as well as ethnic differences in the populations studied provide plausible explanations for the wide variation in results.

The complexity of predicting response to CPT-11 therapy may be further hampered by the lack of ability to assess active drug concentrations within tumour tissue. Influx of SN-38 to the tumour may be dependent on the SN-38 uptake transporter OATP1B3 (SLCO1B3), which our group and others had shown to be highly upregulated in various cancer tissues including colon ([@bib19]; [@bib35]; [@bib27]; [@bib8]). Recently, a cancer-specific isoform of OATP1B3 (csOATP1B3), lacking the first 28 amino acids in colon cancer tissues, has been identified ([@bib25]; [@bib34]). Expression of csOATP1B3 appears to be induced under hypoxic conditions that are often associated with advanced solid cancers and poorer clinical outcomes ([@bib12]). It remains unknown if csOATP1B3 expression is predictive of response to CPT-11 therapy.

Determining the overall contribution of genetic variation in drug transporters as well as metabolising enzymes will be essential to tailoring CPT-11 doses for individual patients. In this study, our primary objective was to better correlate the effects of genetic variation in drug transporters, as well as enzymes such as UGT1A1, with measured CPT-11 and metabolite levels among cancer patients receiving irinotecan-based chemotherapy regimens in a prospective manner. Our secondary objective was to assess the impact of pharmacogenetic factors to the development of adverse events and progression-free survival (PFS). Finally, tumour tissues obtained from a cohort of these patients were analysed for OATP1B3 expression and its effect on PFS.

Materials and Methods
=====================

Study population
----------------

Metastatic colorectal cancer and advanced or metastatic pancreatic cancer patients (*n*=127) being treated with CPT-11-based chemotherapy regimens were prospectively recruited between January 2010 and November 2012 from the London Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada. The majority of patients were prescribed CPT-11 at 180 mg m^−2^ biweekly in combination with 5-fluorouracil and leucovorin (FOLFIRI regimen) with or without bevacuzimab. Patients were included if they were aged 18 years or above with an ECOG (Eastern Cooperative Oncology Group) performance status ⩽2. Exclusion criteria included: \>35 *μ*mol l^−1^ total bilirubin, \>3X upper normal limit AST or ALT without liver metastases or \>5X with liver metastases, known hypersensitivity to CPT-11, known history of Gilbert\'s syndrome, and concurrent use of ketoconazole. All participants provided written informed consent. The study was approved by the Research Ethics Board at Western University.

Chart review
------------

Paper and electronic record chart review for each consented patient was conducted by a single reviewer. Age recorded was the age at initiation of CPT-11-based chemotherapy. A cycle of CPT-11 was defined as a single administration of CPT-11 alone or in combination, irrespective of the chemotherapy regimen used. Treatment-related toxicities were recorded for the cycle where the blood sample was obtained in addition to any toxicities occurring throughout the duration of treatment with CPT-11. The blood sample cycle was considered to extend to the subsequent measurement of basic laboratory values and/or clinical assessment. Toxicities during this period were not considered to be associated with the particular treatment if they were documented more than 3 weeks after sample blood drawn. NCI-CTCAE version 3.0 (Bethesda, MD, USA) was used to grade toxicities. Toxicity grade was determined using subjective measures (described in clinical notes) when exact grading was not documented.

Responders were defined as having a stable or reduced tumour size on the first CT scan following CPT-11-based chemotherapy initiation. The interval between CT scans was at the discretion of the treating oncologist. Progression was defined as the date the CT or MRI reported an increased tumour size. Progression-free survival was considered to be the time from initiation of CPT-11-based chemotherapy to the date of progression, death, last contact, or censor date (13 August 2013), whichever occurred first.

Genotyping
----------

DNA was extracted from whole blood using the Gentra Purgene Blood Kit (Qiagen, Toronto, Ontario, Canada). The following TaqMan allelic discrimination assays (Applied Biosystems, Carlsbad, CA, USA) were used for genotyping: *ABCB1* (*c.3435C\>T*, rs1045642), *ABCG2* (*c.421C\>A*, rs2231142; *c.34G\>A*, rs2231137), *ABCC2* (*c.-24C\>T*, rs717620; *c.1249G\>A*, rs2273697), *ABCC5* (*T\>C*, rs562), *SLCO1B1\*1b* (*c.388A\>G*, rs2306283), *SLCO1B1\*5* (*c.521T\>C*, rs4149056), *SLCO1B3* (*g.699G\>A*, rs7311358), *UGT1A1\*28* (*TA(6/7)*, rs8175347), *CES1* (*g.14506G\>A*, rs71647871; *g.27467A\>C*, rs2244613), *CYP3A4\*22* (*intron 6 C\>T*, rs35599367), and *CYP3A5\*3* (*g.6986A\>G*, rs776746). Hardy--Weinburg equilibrium was assessed for all genotypes using the *χ*^2^ goodness-of-fit test.

Drug levels
-----------

Blood samples were obtained by venipuncture of the opposite arm immediately following the end of the CPT-11 infusion (90 min) during any cycle of CPT-11-based chemotherapy. Plasma was collected and stored at −80 °C until analysis. Plasma concentrations of CPT-11 and metabolites SN-38, SN-38G, and APC (7-ethyl-10-\[4-*N*-(5-aminopentanoic acid)-1-piperidino\] carbonyloxycamptothecin) were measured by liquid chromatography-tandem mass spectrometry. Standards were obtained from Sigma-Aldrich (Oakville, Ontario, Canada; CPT-11, SN-38) and Toronto Research Chemicals (Toronto, Ontario, Canada; SN-38-glucuronide, APC). Plasma samples (100 *μ*l) were precipitated upon addition of 3 volumes of acetonitrile and 0.1% formic acid (FA) spiked with 15 *μ*l internal standard (camptothecin, 500 ng ml^−1^, Toronto Research Chemicals). Samples were vortexed, centrifuged, and diluted with H~2~O (0.1% FA). Analytes were injected (30 *μ*l) into the liquid chromatograph (Agilent 1200) and separated on a reverse-phase column (Hypersil Gold, 50 × 5 mm, 5 *μ*[M]{.smallcaps} particle size) over 6 min using gradient elution with H~2~O (0.1% FA) and acetonitrile (0.1% FA) (10--90%). Standard curves and quality controls (co-efficient of variation (%), high (13.5), med (2.6), low (3.7)) were prepared in drug-free plasma. The mass spectrometer (Thermo TSQ Vantage, Burlington, ON, Canada) with heated electrospray ionisation source was set in positive mode for detection of CPT-11, SN-38, SN-38G, APC, and camptothecin with transitions 587→124 *m/z,* 393→349.3 *m/z*, 569→393.3 *m/z*, 691→227 *m/z*, 349→305 *m/z*, respectively.

Immunohistochemistry
--------------------

Archived normal and tumour tissue biopsy slides were obtained from a subset of study participants (*n*=30) following approval by the Tissue and Archive Committee (Department of Pathology, London Health Sciences Centre). Antigen retrieval was performed with citrate buffer and slides were subsequently incubated with pre-immune serum or anti-OATP1B3 polyclonal antibody (1 : 200) followed by an avidin-biotin immunoperoxidase assay and developed using an AEC (3-Amino-9-ethylcarbazole) staining kit (Sigma-Aldrich) using a modified protocol ([@bib19]). Nuclei were counterstained using Mayer\'s haematoxylin (Sigma-Aldrich). Scoring for OATP1B3 expression in normal, normal adjacent, and tumour tissue was performed independently by one pathologist (JP). Staining intensity for OATP1B3 was defined and evaluated using the following semi-quantitative previously published method: (0) no staining, (1) weakly positive, (2) moderately positive, and (3) strongly positive ([@bib19]).

Statistics
----------

The primary objective was to determine covariates associated with interindividual variability of CPT-11 and metabolite plasma concentration. All statistical analysis was performed in GraphPad Prism and the statistical software R. One-way analysis of variance with Bonferroni correction and Student\'s *t*-tests was used to compare drug levels between genotypic groups. Multiple linear regression analysis was performed to determine significant covariates on the interindividual variability of dose-normalised CPT-11 and metabolite plasma concentrations (natural log-transformed). Covariates considered included: age, sex, treatment regimen, *ABCB1, ABCG2, ABCC2, ABCC5, SLCO1B1, SLCO1B3, UGT1A1, CES1, CYP3A4,* and *CYP3A5* genotype. Covariates were assessed individually and were considered for the final model at a significance level of *P*\<0.2. Covariates meeting these criteria were entered into a multiple linear regression model adjusting for age, sex, and treatment regimen and remained in the final model if *P*\<0.1.

Secondary outcomes included assessing covariates associated with toxicity and PFS. Multinomial logistic regression analysis was used to determine association of genotype with toxicity events after adjustment for sex, age, and treatment regimen. Toxicity categories used in the regression analysis were: neutropenia (no event *vs* low (grade 1 or 2) *vs* high (grade 3 or 4)) and diarrhoea, nausea/vomiting and oral mucositis (no event *vs* low (grade 1) *vs* high (grade 2 or 3)). Univariate analysis was performed for each covariate and only significant genotypes were included in the final model with the exception of adjustment covariates as indicated above. Logistic regression analysis was also performed to determine covariates associated with neutropenia (low (grade 0, 1 or 2) *vs* high (grade 3 or 4)). Cox regression analysis was used to determine association of covariates with PFS in patients treated with BEV-FOLFIRI or FOLFIRI regimens (excluding patients with pancreatic cancer). Univariate analysis was performed and covariates with a cut value of *P*\<0.2 were included in the final multivariate analysis with the exception of adjusting covariates, age at enrolment, sex and treatment regimen. Kruskal--Wallis with Dunn\'s multiple comparative test and Wilcoxon signed rank test was used to compare OATP1B3 pathology scores. Mann--Whitney *U*-test was used to compare OATP1B3 pathology scores and PFS in patients treated with CPT-11-based chemotherapy regimens scored for OATP1B3 tumour expression (0--1 *vs* 2--3).

Results
=======

Study population
----------------

Patient and tumour characteristics (*n*=127) are described in [Table 1](#tbl1){ref-type="table"}. The treatment profile of patients is presented in [Table 2](#tbl2){ref-type="table"}. Approximately half (55%) of the study population had not received previous chemotherapy and the majority of patients (82%) were treated with bevacizumab (BEV)-FOLFIRI or FOLFIRI chemotherapy regimens as first-line therapy ([Table 2](#tbl2){ref-type="table"}).

OATP1B1 and ABCC5 are important determinants of SN-38 and SN-38G levels
-----------------------------------------------------------------------

The primary objective was to determine covariates associated with interindividual variability of plasma concentrations of CPT-11 and metabolites. Plasma concentrations of CPT-11, SN-38, SN-38G, and APC were measured from blood samples collected immediately following the end of CPT-11 infusion. Multiple linear regression was performed on dose-normalised drug levels (natural log transformed) adjusting for age at time of treatment initiation, sex and treatment regimen in the final models. *ABCB1* (*c.3435* C\>T) was significantly associated with CPT-11 exposure as homozygous variant (T/T) carriers had lower levels compared with wild-type patients (*P*\<0.05; [Figure 1A](#fig1){ref-type="fig"} and [Supplementary Table 1](#sup1){ref-type="supplementary-material"}). This model had one significant adjusting covariate (FOLFIRI treatment regimen, *P* \<0.05).

Several genotypes were significantly associated with variation in SN-38 levels as part of a model that explained approximately 27% of the variation in exposure ([Table 3](#tbl3){ref-type="table"}). *SLCO1B1 521C* allele carriers had significantly increased systemic exposure to SN-38 (*P*\<0.001, [Figure 1B](#fig1){ref-type="fig"}). As expected, heterozygous (\*1/\*28) and homozygous variant (\*28/\*28) *UGT1A1* carriers had increased SN-38 plasma levels ([Figure 1C](#fig1){ref-type="fig"}). Interestingly, a significant increase in SN-38 level was observed with an increasing number of combined *SLCO1B1 521C* and *UGT1A1\*28* variant alleles, suggesting an additive effect of polymorphisms in these two genes ([Figure 1D](#fig1){ref-type="fig"}). A corresponding decrease in the SN-38G/SN-38 ratio was observed with an increasing number of combined variant alleles ([Figure 1E](#fig1){ref-type="fig"}). Together, this suggests that patients heterozygous for both *SLCO1B1 521C* and *UGT1A1\*28* may have an equivalent risk of increased SN-38 exposure compared with patients homozygous for either polymorphism, respectively. Carriers of a rare SNP in *CES1* (rs71647871, allele frequency, 0.024) had significantly decreased SN-38 levels (*P*\<0.05, [Table 3](#tbl3){ref-type="table"}).

Interestingly, SN-38G levels were significantly affected by *ABCC5* genotype. Patients harbouring the *ABCC5* rs562 C allele had reduced SN-38G plasma exposure compared with wild-type patients (*P* \<0.001, [Figure 1F](#fig1){ref-type="fig"}, [Supplementary Table 2](#sup1){ref-type="supplementary-material"}). In addition, patients expressing CYP3A5 also had significantly reduced SN-38G plasma levels (*P* \<0.05). FOLFIRI and FOLFIRINOX treatment regimens were significantly associated with SN-38G (*P*\<0.001 and *P* \<0.05, respectively).

The model for the inactive metabolite APC explained approximately 24% of the variability in plasma exposure ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}). *SLCO1B3 g.699* and *ABCC2 c.1249G\>A* were positively associated with APC levels (*P\<*0.01). Decreased plasma levels were observed in patients carrying the *ABCC5* rs562 C allele compared with wild-type patients (*P*\<0.001). Significant adjusting covariates in this model included sex (*P*\<0.05) and treatment regimen (*P*\<0.01).

Drug transporters predict CPT-11-related toxicities
---------------------------------------------------

CPT-11-related adverse reactions and frequencies of grade severity are described in [Supplementary Table 4](#sup1){ref-type="supplementary-material"}. Multinomial logistic regression analysis was performed to determine association of genotypes to adverse reactions comparing no event *vs* low-grade *vs* high-grade toxicity ([Table 4](#tbl4){ref-type="table"}). *ABCC2 -24C/T* carriers had significantly lower risk of grade 3/4 neutropenia compared with wild-type patients (odds ratio (OR)=0.22, 95% CI=0.06--0.85). *UGT1A1\*28* carriers were at increased risk for severe neutropenia (grade 3/4) compared with wild-type patients following binary logistic regression analysing low- *vs* high-grade events (OR=3.67; 95% CI=1.19--11.33; [Table 4](#tbl4){ref-type="table"}). In addition to their increased SN-38 exposure, patients with two or more combined *SLCO1B1 521C* and *UGT1A1\*28* variant alleles were also at significantly increased risk of severe neutropenia (grade 3/4) compared with patients wild-type for both alleles (OR=4.154, 95% CI=1.06--16.36).

Non-haematological toxicity was associated with drug transporters and metabolising enzymes ([Table 4](#tbl4){ref-type="table"}). Carriers of a common SNP in *CES1* (rs2244613) had significantly lower risk of higher-grade diarrhoea (OR=0.29, 95% CI=0.09--0.89). Patients with *ABCB1 3435 C/T* and *T/T* genotypes were much more likely to experience higher-grade nausea/vomiting (OR=9.06, 95% CI=1.03--79.41 and OR=10.52, 95% CI=1.10--100.2, respectively). Higher-grade oral mucositis was observed in patients expressing CYP3A5 (OR=8.10, 95% CI=1.57--41.90), whereas those heterozygous for *SLCO1B1 388A/G* had a significantly lower risk (OR=0.19, 95% CI=0.05--0.72). No significant adjusting covariates were found in the binary logistic or multinomial logistic regression models.

Biomarkers of PFS
-----------------

Approximately 73% of patients were considered responders having radiographic evidence of no change or tumour shrinkage during CPT-11-based therapy. At the time of analysis (censor date: 13 August 2013), disease progression was evident in the majority of patients with a median PFS time of 10.5 months (range, 0.2--43 months; [Table 2](#tbl2){ref-type="table"}). Cox-regression analysis for PFS was performed on patients (excluding pancreatic cancer patients) treated with BEV-FOLFIRI or FOLFIRI regimens only (*n*=103, [Table 5](#tbl5){ref-type="table"}). Patients homozygous for *SLCO1B1 388G/G* alleles had a significantly increased PFS compared with wild-type patients (HR=1.60, 95% CI=1.04--2.46). Patients carrying two *ABCC2 c.-24T* alleles had decreased PFS (HR=0.62, 95% CI=0.40--0.95). Reduced PFS was also observed for *UGT1A1\*28* (\*1/\*28, HR=0.69, 95% CI=0.52--0.92; \*28/\*28, HR=0.60, 95% CI=0.38--0.97). ABCC5 was associated with PFS in the univariate analysis (*P*=0.05), but did not remain significant following adjustment in the final model. No significant adjusting covariates were found in the multivariate analysis.

Tumour OATP1B3 expression suggests poorer clinical outcomes
-----------------------------------------------------------

The role of OATP1B3 expression, known to transport SN-38, in response to CPT-11-based chemotherapy is unknown. Recently, OATP1B3 expression within colon tumours has been shown to be a cancer-specific isoform that may be expressed primarily as an intracellular protein calling into question the functional relevance of this transporter within the tumour ([@bib34]). Paired normal and tumour samples were available for a subset of patients treated with CPT-11-based chemotherapy regimens (*n*=30: BEV-FOLFIRI, *n*=22; FOLFIRI, *n*=5; FOLFIRINOX, *n*=1; BEV-irinotecan, *n*=1; cetuximab-irinotecan, *n*=1). Staining for OATP1B3 was performed and intensity of expression was scored. Tumour tissue had a significantly higher OATP1B3 score compared with paired normal tissue (*P*\<0.05, [Figure 2A and C](#fig2){ref-type="fig"}). Progression-free survival was significantly reduced in patients with high (score, 2 or 3) OATP1B3 expression compared with patients with low (score, 0 or 1) expression ([Figure 2B](#fig2){ref-type="fig"}), suggesting that OATP1B3 expression may correlate with poorer clinical response to CPT-11 therapy.

Discussion
==========

Pharmacogenetics of irinotecan therapy has been widely studied and *UGT1A1\*28* in particular, shown to be of potential clinical relevance especially for patients prescribed high-dose CPT-11 therapy ([@bib13]). As severe toxicities are often observed in patients treated with combination regimens at lower CPT-11 doses, we examined pharmacogenetic determinants of CPT-11 and metabolite exposure in this setting.

SN-38 plasma exposure was significantly increased *SLCO1B1 521C* (*\*5*) allele carriers (*P*\<0.001) ([Figure 3](#fig3){ref-type="fig"}) consistent with studies correlating *SLCO1B1 521C* to higher SN-38 and CPT-11 AUC in both colorectal cancer and non-small-lung cell cancer patients ([@bib11]; [@bib16]). *UGT1A1\*28* carriers had significantly increased SN-38 levels compared with non-carriers (*P*\<0.01) consistent with previous reports, which can result in greater toxicity risk ([@bib17]; [@bib16]; [@bib14]; [@bib31]; [@bib4]). Importantly, we demonstrate an additive effect of *SLCO1B1 521C* and *UGT1A1\*28* on SN-38 exposure as patients with an increasing number of combined variant alleles had higher plasma levels and a corresponding decrease in the SN-38G/SN-38 ratio. To our knowledge this is the first report of an additive effect in a primarily Caucasian (94%) population, which remained significant upon exclusion of non-Caucasian patients. A similar additive effect has been noted for SN-38 AUC with combined *SLCO1B1\*15* and *UGT1A1\*6* or *\*28* polymorphisms in Japanese patients, likely due to the presence of the *SLCO1B1 521C* allele ([@bib31]). Together, these results suggest that heterozygous carriers of both *SLCO1B1 521C* and *UGT1A1\*28* may reach a toxicity risk comparable to homozygous *UGT1A1\*28* patients as evidenced by several case reports of *SLCO521C* and *UGT1A1\*28* carriers presenting with life-threatening toxicities ([@bib32]; [@bib33]). Here we observed an OR of 4.15 (95%CI=1.06--16.36) for grade 3/4 neutropenia in patients with two or more combined variant allele. The clinical relevance of the additive effect of these two genes may be underestimated and need to be further examined as a better strategy for personalising CPT-11 therapy.

Although plasma SN-38 levels appear to be the most predictive of toxicity risk, secondary metabolites, SN-38G and APC, may also be important contributors. We observed decreased plasma levels of these metabolites associated with an *ABCC5* polymorphism (rs562) that was recently identified as a significant predictor of GI toxicity ([@bib7]). These effects may be due to reduced ABCC5 hepatic efflux leading to SN-38G and APC accumulation within the liver ([Figure 3](#fig3){ref-type="fig"}). Higher hepatic concentrations may ultimately lead to increased intestinal SN-38G levels, through increased biliary excretion via other ABC transporters, which may then undergo *β*-glucuronidase-dependent reconversion to SN-38 thereby augmenting GI toxicity risk ([Figure 3](#fig3){ref-type="fig"}).

In this study, CPT-11 levels were lower in homozygous *ABCB1 3435T* patients. ABCB1 is a well-established transporter of CPT-11 and SN-38, but its clinical relevance for CPT-11 therapy remains inconclusive. ABCB1 polymorphisms have been associated with both increased or reduced exposure, decreased clearance and increased toxicity and response, whereas other studies were unable to confirm these results ([@bib24]; [@bib30]; [@bib22]; [@bib5]; [@bib16]; [@bib31]; [@bib10]). This may be due to the redundancy of other transporters, including ABCC2 and ABCG2, capable of biliary excretion of CPT-11 and metabolites. The lack of consistent evidence suggests that ABCB1 may not be useful in personalising CPT-11 therapy.

As a secondary objective we examined the impact of pharmacogenetic factors on adverse events and PFS. Here, the majority (97%) of patients were prescribed 180 mg m^−2^ CPT-11 with 17% experiencing severe neutropenia. Neutropenia was associated with *UGT1A1\*28* as has been reported ([@bib13]). More importantly, patients carrying two or more combined *SLCO1B1 521C* and *UGT1A1\*28* alleles were at significantly increased risk of myelosuppression, suggesting these SNPs together may provide a more comprehensive strategy for assessing haematological toxicity risk. Heterozygous *ABCC2--24C/T* but not *TT* carriers predicted reduced neutropenia risk indicating further validation is needed.

Non-haematological toxicities including diarrhoea, nausea/vomiting, and oral mucositis were assessed. Most notably, a common SNP in *CES1* (rs2244613) was associated with lower risk of diarrhoea, which may be due to reduced conversion of CPT-11 to SN-38. *CES1* (rs2244613) was recently associated with reduced trough levels of dabigatran, a new oral anticoagulant drug, and a significantly decreased bleeding risk in patients, suggesting this SNP may be clinically relevant for many CES-dependent drugs ([@bib28]). Interestingly, homozygous *ABCB1 3435T* carriers had a much higher likelihood of experiencing higher-grade nausea/vomiting (OR=10.52, *P*\<0.05) and patients expressing CYP3A5 had a significantly increased risk of oral mucositis, suggesting higher levels of M4, APC, or NPC metabolites may contribute its development. A potential limitation to this analysis is the concurrent use of 5-fluorouracil with CPT-11 in most patients. Although the side-effect profile of the two drugs is similar, the majority of markers assessed are not specific to 5-fluorouracil, suggesting these correlations are likely due to modulation of irinotecan disposition but require confirmation in a study designed to assess toxicity as a primary objective.

PFS analysis was limited to patients treated with FOLFIRI with or without BEV. *SLCO1B1 388*(*G/G*) was associated with longer PFS, suggesting variant carriers may experience better response to FOLFIRI-based regimens. This effect may be due to increased OATP1B1 expression as this variant has recently been correlated to increased expression in Caucasian liver samples ([@bib26]). *ABCC2--24TT* was associated with reduced PFS, consistent with lower response rates and shorter PFS observed in Japanese patients, but contrary to the lack of association in Caucasian metastatic colorectal cancer patients treated with FOLFIRI regimes ([@bib2]). *UGT1A1\*28* was also associated with reduced PFS, but a recent meta-analysis suggested that *UGT1A1\*28* status may not be a reliable predictor of PFS ([@bib20]). Our evaluation of PFS may be confounded by patients still undergoing active therapy or surveillance at the date of censoring. Although the genes investigated are not thought to have a role in the other drugs in the FOLFIRI regimen, we cannot rule out the effect of these drugs on PFS.

Importantly, we analysed OATP1B3 tumour expression in a subset of patients. To date, tumour biomarkers of CPT-11 response remain unknown. Our group was the first to note OATP1B3 overexpression in colon tumours and this expression was recently identified exclusively as a cancer-specific (cs)OATP1B3 splice variant ([@bib19]; [@bib12]; [@bib15]; [@bib34]). The localisation (thought to be intracellular), function, and clinical relevance of csOATP1B3 are under investigation ([@bib15]; [@bib34]). Here we show the first evidence, to our knowledge, that higher OATP1B3 expression in colon tumours was significantly associated with reduced PFS ([Figure 3](#fig3){ref-type="fig"}). Lack of membrane expression of a functional OATP1B3 transporter may lead to reduced SN-38 tumour influx leading to a poorer clinical response or alternatively, overexpression of csOATP1B3 within the tumour may induce a p53-dependent survival mechanism, which has been demonstrated in WT-OATP1B3 colon cancer cell lines ([@bib19]). Although we are unable to definitively confirm OATP1B3 to be the cancer-specific isoform due to use of an antibody recognising the common c-terminal region, the reported lack of wild-type OATP1B3 expression within colon tumours suggests this is the form expressed in these tumours ([@bib34]).

Owing to the complexity of CPT-11 disposition, it is questionable that one gene alone will be useful for personalising therapy and will likely require assessing the right combination of genes. Our data provide new insight regarding transporters, particularly members of the OATP1B subfamily, to the disposition and clinical effects of CPT-11 (summarised in [Figure 3](#fig3){ref-type="fig"}). The additive effect of *SLCO1B1 521C* and *UGT1A1\*28* on SN-38 exposure and neutropenia risk seen here in patients carrying two or more combined alleles (24.8% of this population) provides rationale for examining the utility of combined genotyping to better predict toxicity risk in CPT-11-based regimens. Future prospective studies should be designed to compare combined genotyping to *UGT1A1\*28* genotyping alone to advance the goal of personalising irinotecan.

We thank Cameron Ross and Sara Mansell for their technical assistance. We also thank Drs Mary Mackenzie, Ian Kerr, Michael Sanatani, Michael Ong, Mark Vincent, and Shadu Al-Khayyat and all the members of the GI Disease Site Team at the London Regional Cancer Program (LRCP). Dr RB Kim holds the Wolfe Medical Research Chair in Pharmacogenomics at Western. This study was funded by the Cancer Care Ontario (CCO) Research Chair Award (Tier-1) in Experimental Therapeutics (RB Kim). In addition, this study was conducted with the support of the Ontario Institute for Cancer Research through funding provided by the Government of Ontario.

[Supplementary Information](#sup1){ref-type="supplementary-material"} accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.

The authors declare no conflict of interest.

Supplementary Material {#sup1}
======================

###### 

Click here for additional data file.

![**Association between genotype and CPT-11 and metabolite plasma concentrations.** (**A**) Effect of *ABCB1 3435C\>T* genotype on dose-normalised CPT-11 plasma levels. Association between *SLCO1B1 521T\>C* (**B**) and *UGT1A1\*28* (**C**) genotype and dose-normalised SN-38 levels. Effect of increasing number of combined *SLCO1B1 521C* and *UGT1A1\*28* variant alleles on dose-normalised SN-38 plasma levels (**D**) and plasma SN-38-G/SN-38 ratio (**E**). (**F**) Association between *ABCC5 rs562 T\>C* genotype and SN-38-G plasma levels. \*\<0.05, \*\*\<0.01, \*\*\*\<0.001.](bjc20155f1){#fig1}

![**Effect of OATP1B3 tumour expression on progression-free survival in patients treated with CPT-11-based chemotherapy regimen.** (**A**) Pathology score of OATP1B3 expression in paired samples of normal, normal adjacent, and tumour tissue (*n*=30). (**B**) Association between OATP1B3 tumour score and progression-free survival in patients. (**C**) Representative immunohistochemistry of OATP1B3 expression in normal and tumour colon tissue. \*\<0.05.](bjc20155f2){#fig2}

![**Schematic model depicting known and new insight into the metabolism and transport of CPT-11, SN-38, and SN-38G and the proposed effect on treatment-related toxicities and response.** Increased SN-38 exposure due to combined SLCO1B1 and UGT1A1 variants correlates with an increased risk for neutropenia. Increased intestinal SN-38G, due to reduced ABCC5 hepatic efflux, may lead to increased risk for diarrhoea as SN-38G is converted to SN-38 via intestinal *β*-glucoronidases. Circles with check marks indicate an effect on neutropenia (N), diarrhea (D), and progression-free survival (P).](bjc20155f3){#fig3}

###### Patient and tumour characteristics (*n*=127)

  **Variable**                        ***n*** **(%)**
  ---------------------------------- -----------------
  **Demographics**                   
  Male                                   86 (67.7)
  Median age; range (years)             61; 27--83
  Ethnicity (Caucasian)                 119 (93.7)
  **ECOG status**                    
  0                                      61 (48.0)
  1                                      50 (39.4)
  2                                       2 (1.6)
  **Tumour histology**               
  Colon                                  62 (48.8)
  Rectal                                 45 (35.4)
  Pancreatic                             13 (10.2)
  Other[a](#t1-fn2){ref-type="fn"}        7 (5.5)
  **Tumour grade**                   
  Grade 1                                84 (65.6)
  Grade 2                                25 (19.5)
  Grade 3                                13 (10.2)
  **Number of metastases**           
  ⩽2                                     24 (18.8)
  3--4                                   22 (17.2)
  \>4                                    80 (62.5)
  **Location of metastases**         
  Liver                                  95 (74.2)
  Lung                                   51 (39.8)
  Peritoneum                             37 (28.9)
  Bone                                   16 (12.5)
  Brain                                   4 (3.1)
  Other                                  11 (8.6)

Abbreviation: ECOG=Eastern Cooperative Oncology Group.

Includes unknown primary, appendiceal carcinoid, neuroendocrine, gall bladder, signet ring cell.

###### Treatment profile (*n*=127)

  **Variable**                                       ***n*** **(%)**
  ------------------------------------------------ -------------------
  **Previous chemotherapy**                        
  No                                                    70 (55.1)
  One line                                              40 (31.5)
  Two or more lines                                     17 (13.4)
  **Irinotecan-based chemotherapy administered**   
  Bevacizumab-FOLFIRI                                   85 (66.9)
  FOLFIRI                                               19 (15.0)
  FOLFIRINOX                                            14 (11.0)
  Irinotecan                                             8 (6.3)
  **Further treatment provided**                   
  Chemotherapy                                          66 (52.5)
  Surgical metastectomy                                 13 (10.2)
  **No. of prior cycles of irinotecan**            
  0--1                                                  34 (27.6)
  2--4                                                  41 (33.3)
  ⩾5                                                    48 (39.0)
  **Dose reduction at sample draw**                
  No. of reduction                                      77 (60.6)
  ⩽20%                                                  29 (22.9)
  \>20%                                                 21 (16.5)
  **Outcomes**                                     
  Responder                                             93 (73.2)
  Median PFS; range (months)                        10.5 (0.2---43.0)

Abbreviations: FOLFIRI=5-fluorouracil, irinotecan, leucovorin; FOLFIRINOX=5-fluorouracil, irinotecan, leucovorin, oxaliplatin; PFS=progression-free survival.

###### Multiple linear regression model for effect on Ln-transformed SN-38 concentration (adjusted R squared 0.2686), (*n* =127)

  **Predictor variable**                             **Estimate**   **Standard error**   ***P***
  ------------------------------------------------- -------------- -------------------- ---------
  Intercept                                             −0.732            0.269          \<0.01
  FOLFIRI regimen                                       0.160             0.104           0.124
  FOLFIRINOX regimen                                    −0.108            0.120           0.367
  Other CPT-11 regimen[a](#t3-fn2){ref-type="fn"}       0.037             0.146           0.802
  Male sex                                              0.092             0.079           0.250
  Age                                                   0.008             0.004           0.063
  ABCB1 c.3435 (C/T)                                    0.015             0.096           0.872
  ABCB1 c.3435 (T/T)                                    −0.202            0.112           0.074
  SLCO1B1 c.521 (T/C;C/C)                               0.269             0.080           0.001
  UGT1A1 (\*1/\*28)                                     0.200             0.077           0.011
  UGT1A1 (\*28/\*28)                                    0.456             0.137           0.001
  CES1 rs71647871 (G/A)                                 −0.341            0.171           0.048

Abbreviations: FOLFIRI=5-fluorouracil, irinotecan, leucovorin; FOLFIRINOX=5-fluorouracil, irinotecan, leucovorin, oxaliplatin.

Other CPT-11 regimen includes irinotecan as a single agent, irinotecan +cetuximab, 5-FU-irinotecan +cetuximab.

###### Association between genotype and toxicity (*n* =127)

  **Toxicity and covariate**                                                                      **OR**    **95% CI**    **Multivariate** ***P***[a](#t4-fn2){ref-type="fn"}   **Univariate** ***P***
  ---------------------------------------------------------------------------------------------- -------- -------------- ----------------------------------------------------- ------------------------
  **Binary logistic regression (low *vs* high)**[b](#t4-fn3){ref-type="fn"}                                                                                                    
  **Neutropenia**                                                                                                                                                                          
   UGT1A1\*28 carriers                                                                             3.67    1.19---11.33                       **\<0.05**                              **\<0.05**
  **Multinomial logistic regression (no event *vs* low *vs* high)**[c](#t4-fn4){ref-type="fn"}                                                                                 
  **Neutropenia**                                                                                                                                                                          
   ABCC2--24 C/T                                                                                   0.22    0.06---0.85                        **\<0.05**                                 0.07
   ABCC2--24 T/T                                                                                   0.84    0.63---1.23                           0.85                                    0.08
  **Diarrhoea**                                                                                                                                                                            
   CES1 rs2244613                                                                                  0.29    0.09---0.89                        **\<0.05**                              **\<0.05**
  **Nausea/vomiting**                                                                                                                                                                      
   ABCB1 3435 C/T                                                                                  9.06    1.03---79.41                          0.06                                    0.09
   ABCB1 3435 T/T                                                                                 10.52    1.10---100.2                       **\<0.05**                                 0.05
  **Oral mucositis**                                                                                                                                                                       
   CYP3A5\*3                                                                                       8.1     1.57---41.90                       **\<0.05**                              **\<0.05**
   SLCO1B1 388A/G                                                                                  0.19    0.05---0.72                        **\<0.05**                              **\<0.05**
   SLCO1B1 388G/G                                                                                  0.62    0.13---2.99                           0.55                                    0.74

Abbreviations: OR=odds ratio; CI=confidence interval.

Adjusted for age at enrolment, sex, and treatment regimen.

Low=grades 0, 1, and 2; high grade=grade 3 and 4.

Results are shown for no event *vs* high regression where high was considered as grade 3/4 (neutropenia) and grade 2/3 (diarrhoea, nausea/vomiting, and oral mucositis).

###### Association of genotypes and progression-free survival (*n*=103)

  **Genotype**              **No. of patients**    **HR**    **95% CI**   **Multivariate*****P***[a](#t5-fn2){ref-type="fn"}    **Univariate** ***P***
  ------------------------ --------------------- ---------- ------------- ---------------------------------------------------- ------------------------
  SLCO1B1\*1b (388 A\>G)                            1.27     1.05---1.54                                                              **\<0.05**
  A/A                               35              1.00                                                                                   
  A/G                               52              1.02     0.76---1.37  0.92                                                             
  **G/G**                           16            **1.60**   1.04---2.46  **\<0.05**                                                       
  ABCC2 (-24 C\>T)                                  0.84     0.68---1.03                                                                 0.09
  C/C                               60              1.00                                                                                   
  C/T                               33              0.99     0.73---1.35  0.97                                                             
  **T/T**                           10            **0.62**   0.40---0.95  **\<0.05**                                                       
  UGT1A1\*28                                        0.75     0.62---0.93                                                              **\<0.01**
  6/6                               46              1.00                                                                                   
  **6/7**                           49            **0.69**   0.52---0.92  **\<0.05**                                                       
  **7/7**                            8            **0.60**   0.38---0.97  **\<0.05**                                                       
  ABCC5 (rs562 T\>C)                                0.81     0.66---1.00                                                               **0.05**

Abbreviations: HR=hazard ratio; CI=confidence interval. Bold entries are to signify their statistical significance.

Adjusted for age at enrolment, sex, and treatment regimen (FOLFIRI).
